pharmaceutical investing Zosano Pharma Announces 3.8mg Dose of M207, its Novel Transdermal Therapeutic, Meets Both Co-primary Endpoints in the ZOTRIP Pivotal Efficacy Trial in Migraine
Biotie Therapies Corp. Announces That the Delisting of Its American Depositary Shares from NASDAQ Global Select Market Has Become Effective
Alvopetro Announces Year End 2025 Financial Results, Q1 2026 Dividend of US$0.12/share, and Filing of our AIF
QIMC Reports Results from Hole 1 DDH-26-01 at West-Advocate Natural Hydrogen Project, Nova Scotia; R2G2(TM) Exploration Model Applied
